Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4000-4007

  Keller, Josbert J ^a   Offerhaus, G Johan A ^a   Drillenburg, Paul ^a   Caspers, Eric ^a   Musler, Alex ^a   Ristimäki, Ari ^b   Giardiello, Francis M ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SULINDAC;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER REGRESSION; CHROMOSOME 5Q; CLINICAL ARTICLE; FAMILIAL POLYPOSIS; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM ADENOMA;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BETA CATENIN; CODON; CYCLOOXYGENASE 2; CYTOSKELETAL PROTEINS; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LOSS OF HETEROZYGOSITY; MEMBRANE PROTEINS; MUTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECTAL NEOPLASMS; SULINDAC; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035679823     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention
2. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
3. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
4. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis
5. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis
6. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac
7. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration
8. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
9. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)
10. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
11. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis
12. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
13. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
14. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
15. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
16. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
17. Inhibition of β-catenin translocation - A novel explanation for the protective effect of NSAIDs in colorectal cancer
18. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action
19. Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis
20. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
21. Aberrant crypt foci of the colon as precursors of adenoma and cancer
22. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: Evaluation of predictive factors
23. Rectal cancer in FAP patient after sulindac
24. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy
25. Role of BAX in the apoptotic response to anticancer agents
26. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes
27. Reduced COX-2 protein in colorectal cancer with defective mismatch repair
28. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome
29. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
30. Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations
31. Molecular evidence of field cancerization in a patient with 7 tumors of the aerodigestive tract
32. Alteration of β-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients
33. Reciprocity between membranous and nuclear expression of β-catenin in colorectal tumours
34. β-catenin expression in primary and metastatic colorectal carcinoma
35. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC
36. Nuclear-cytoplasmic shuttling of APC regulates β-catenin subcellular localization and turnover
37. Chemoprevention of intestinal polyposis in the Apcδ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
38. Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice
39. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate
40. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
41. Genetic alterations during colorectal-tumor development
42. Combinatorial chemoprevention of intestinal neoplasia